Taizhou, China, and Ingelheim, Germany – 30 May, 2012 – Today the research based pharmaceutical company Boehringer Ingelheim and Taizhou China Medical City in Jiangsu Province, China, announced the signing of an agreement for the establishment of a veterinary vaccine manufacturing plant. Under the terms of the agreement, the plant will be built in Taizhou China Medical City, a national pharmaceutical high-tech industry park. The total investment will be more than 55.5 million euro. Upon completion, the facility will become a leading manufacturer for veterinary vaccines in Asia. The signing of the agreement, following the launch of the Boehringer Ingelheim Asian Veterinary Research & Development (R&D) Center in Zhangjiang, Shanghai, in March 2012 marks another major step by Boehringer Ingelheim to continue the expansion of its animal health business in China.
“The move underlines our long-term commitment to China”, said Hubertus von Baumbach, responsible for the Corporate Board Divisions Finance and Animal Health. “We are a global leader in animal health, particularly in the swine vaccine sector. With the signing of the joint venture agreement we commit ourselves to bring the entire value chain of our vaccine business to China: R&D, manufacturing and sales.”
“Taizhou China Medical City, with its favourable geographic location, sound investment environment and well qualified employees, among many other things, proves to be an ideal partner for Boehringer Ingelheim”, George Heidgerken, Senior Vice President Boehringer Ingelheim Animal Health.
